Duration of review processes for references cited in a JCVI Report on Covid-19 vaccination
| Article title . | Journal (JCR rank) . | Year . | Duration of review in day . |
|---|---|---|---|
| SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. | J Infection (1,256) | 2020 | 5 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase ½, single-blind, randomised controlled trial. | Lancet (5) | 2020 | 6 |
| Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced CoVID-19 outbreak investigations in London care Homes. | J Infection (1,256) | 2020 | 6 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. | Lancet (5) | 2021 | 9 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. | Lancet (5) | 2020 | 11 |
| Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. | Nature (14) | 2020 | 36 |
| Factors associated with COVID-19-related death using OpenSAFELY. | Nature (14) | 2020 | 47 |
| ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. | Nature (14) | 2021 | 72 |
| Median | 11 | ||
| Article title . | Journal (JCR rank) . | Year . | Duration of review in day . |
|---|---|---|---|
| SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. | J Infection (1,256) | 2020 | 5 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase ½, single-blind, randomised controlled trial. | Lancet (5) | 2020 | 6 |
| Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced CoVID-19 outbreak investigations in London care Homes. | J Infection (1,256) | 2020 | 6 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. | Lancet (5) | 2021 | 9 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. | Lancet (5) | 2020 | 11 |
| Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. | Nature (14) | 2020 | 36 |
| Factors associated with COVID-19-related death using OpenSAFELY. | Nature (14) | 2020 | 47 |
| ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. | Nature (14) | 2021 | 72 |
| Median | 11 | ||